Opioid Use Disorder Market
KEY MARKET INSIGHTS
The global Opioid Use Disorder (OUD) Market size was valued at USD 2.88 billion in 2023 and is projected to grow from USD 3.11 billion in 2022 to USD 5.64 billion by 2030, exhibiting a CAGR of 8.9% during the forecast period. Based on our analysis, the global market exhibited a decline of -10.1% in 2020 as compared to 2019. The global COVID-19 pandemic has been unprecedented and staggering, with opioid use disorder experiencing lower-than-anticipated demand across all regions compared to pre-pandemic levels.
Opioid Use condition (OUD) is a complicated condition characterised by the compelling use of opioid medicines, even if the individual wishes to quit or if the drugs significantly impact the person's mental and physical well-being. Buprenorphine, methadone, and naltrexone are the three pharmacological groups used in the pharmaceutical therapy. These are the only drug classes authorised by the FDA in the United States.
The number of prescriptions for painkillers, which commonly contain opioids, is expected to climb as the worldwide population of individuals suffering from chronic pain grows. When these opioid-based medications are used and the patient's suffering is relieved, the patient's reliance or addiction to these drugs rises. This addiction is dangerous since an opioid overdose can result in death or lifelong impairment of a person's normal psychological and physiological functioning.
Several governments, like the United States, have put laws in place to successfully handle this condition in order to lessen the risk. These legislative reforms, together with the increasing number of product releases by big corporations, are expected to have a positive influence on the sector.
POST COVID-19 IMPACT
Reduced Demand for Medications amid COVID-19 Pandemic to Negatively Impact Market Growth?
Depending on the demand, the COVID-19 pandemic had both beneficial and bad effects on pharmaceutical firms. Certain pharmaceutical items saw a drop in demand as fewer individuals risked visiting healthcare institutions such as hospitals and clinics. To stop the spread of the coronavirus epidemic, the different governments ordered strict national lockdowns. As a consequence, patient visits to hospitals decreased dramatically. Non-essential medical services cancellation or delay impacted market development as well.
On the other side, there was a noticeable increase in patients having opioid overdoses and relapses in the OUD market. However, well-known firms in the field, such as Indivior, saw a significant drop in product sales during this time. Sales continued to fall sharply as a result of Covid-19-related problems. As a result, the worldwide market saw a negative trend during the epidemic.
LATEST TRENDS
Increasing Consideration of Buprenorphine Patches as an Effective Treatment Mode to Propel Market Growth
The industry has lately seen an increase in the demand for buprenorphine treatment patches. These patches are regarded as an effective medication for the treatment of opioid use disorders. The numerous advantages associated with transdermal patches, such as ease of medication delivery and decreased discomfort, are customary and self-administered. Furthermore, these transdermal patches may be a viable option for individuals requiring round-the-clock opioid medication for opioid use disorder.
In 2019, for example, WellSpan Health collaborated with York Opioid Collaborative to conduct a clinical study to develop a Lidocaine patch for the treatment of OUD. During the projected period, such collaboration is expected to boost treatment uptake. Furthermore, increased patient participation is expected to drive worldwide Opioid Use Disorder (OUD) market growth throughout the forecast period.
DRIVING FACTORS
Growing Opioid Addiction Cases to Augment the OUD Market Share?
The worldwide population is today suffering from a variety of severe and chronic ailments, including pain, cancer, cardiovascular disease, and other problems. To treat these problems, painkillers, particularly opioids, are used. Drug usage frequently leads to drug addiction in the patient. The patient is expected to have drug withdrawal symptoms as a result of their increasing reliance on these drugs and their sudden discontinuation.
-
According to the National Drug Dependence Treatment Centre's (NDDTC) Magnitude of Substance Use in India report published in February 2019, the prevalence of current opioid use is 2.06%, and approximately 0.55% of Indians are expected to require help for opioid use problems (harmful use and dependence).
On account of these factors, the likelihood that patients will experience tragic outcomes, such as death induced by an opioid overdose, rises.
Growing Focus of Government & Non-government Institutions to Support Expansion
Another major driving reason driving market development is the growing involvement of governmental and non-governmental organisations in raising awareness about opioid overdose and associated consequences. The number of opioid addicts has substantially grown, prompting various organisations to take a more comprehensive strategy to combating the problem. Numerous countries have increased their efforts to support patients and reduce the effects of opioid addiction.
For example, in March 2022, the Department of Health and Human Services (HHS) announced financing for substance use treatment and prevention programmes in order to increase access to medication-assisted treatment for opioid use disorder and prevent prescription drug misuse.
Similarly, similar programmes are expected to encourage more people suffering from opioid addiction to seek treatment. These factors are expected to have a positive impact on the worldwide market throughout the forecast period.
RESTRAINING FACTORS
Adverse Effects of OUD Drugs to Restrain Market Growth?
-
The adverse effects of the medications used to treat opioid addiction are expected to stymie the market throughout the projected period.
-
These medicines commonly cause muscular pains, vomiting, diarrhoea, bone/joint pain, respiratory difficulties, bladder discomfort, constipation, and stomach cramps. Furthermore, in severe situations of adverse medication response, the patient may suffer from depression and other psychological issues.
-
The hazards connected with these pharmaceuticals have resulted in a warning from the US Food and Drug Administration, which has a negative influence on the drug class, lowering the adoption of medications in this form of treatment.
-
For instance, in January 2022, the U.S. FDA warned about dental problems with buprenorphine medicines dissolved in the mouth to treat OUD and pain. Dental issues, including oral infections, cavities, tooth decay, and teeth loss can be serious and have been reported even in patients with no history of dental issues.
?Such factors might hamper the market growth during the forecast period to a certain extent.
MARKET SEGMENTATION
By Drug Class Analysis
Buprenorphine Segment to Grow at a Faster Pace in the Coming Years
The market is divided into three segments based on drug class: methadone, buprenorphine, and naltrexone.In 2023, the buprenorphine category held the greatest market share. The dominance is attributable to the increased use of these medications in developed nations such as the United States and France, as well as the availability of multiple branded products in this area. SUBLOCADE, SUBOXONE, and ZUBSOLV are some key buprenorphine products.The methadone sector is expected to develop at a slower rate because to an increase in generic product offers and a relative dearth of new product releases in this area.Because of the relatively restricted number of product options, the naltrexone sector is expected to have a smaller market share throughout the projection period.
By Route of Administration
Parenteral Segment to Account for the Highest Market Share
The market is divided into oral and parenteral delivery routes.
Because of the availability of numerous types of OUD medications in varied doses in the parenteral form, the parenteral segment is expected to account for the largest market share over the projection period. As a result, this kind of medication administration continues to dominate the global market.
The oral category is expected to have a lower worldwide market share. However, it is predicted to develop significantly since many people prefer oral medicine administration over injectable drug administration.
By Distribution Channel
Hospital Pharmacies Segment to Dominate Market?
-
The market can be divided into three categories based on distribution channel: hospital pharmacies, retail pharmacies & stores, and online pharmacies.
-
The hospital pharmacies segment is expected to account for the largest share of the global market due to the patient population's reliance on these settings for the administration of parenteral OUD drugs such as buprenorphine.
-
On the other hand, the online pharmacies market is expected to develop at the fastest CAGR since a rising number of patients have been utilising online pharmacies to obtain their medications due to the ease associated with these settings.
REGIONAL INSIGHTS
The North America market was valued at USD 2.23 billion in 2023, and the region is expected to be dominant during the forecast period due to the large number of people in the United States suffering from opioid addiction, the presence of prominent players in the region, and the government's increasing involvement in combating the pandemic. According to a 2020 article released by the National Centre for Biotechnology Information (NCBI), roughly 2.1 million people in the United States suffer with Opioid Use Disorder.
Europe is expected to rank second in the market. This is due to an increase in the number of new product releases in the region as well as an increase in the number of patients suffering from opioid addiction.
Because of rising public awareness of OUD, the Asia Pacific market is expected to grow at the fastest rate in the near future. Furthermore, the region's large patient population and rising healthcare spending are projected to favour industry expansion.
The remainder of the globe comprises of previously underserved regions such as Latin America and the Middle East and Africa. However, the rising number of patients suffering from opioid addiction, rising healthcare spending, and rising awareness are projected to drive market expansion in the approaching years.
KEY PLAYERS
Robust and Diversified Product Portfolios of Indivior PLC, Alkermes, and Orexo AB Led to their Market Dominance
In terms of competitiveness, some significant businesses that dominate the worldwide market are Indivior PLC, Alkermes, and Orexo AB. These three firms accounted for a sizable share of the Opioid Use Disorder market.
The competitive environment shows these significant firms' dominance due to their robust product portfolio in terms of buprenorphine and naltrexone product offers. Furthermore, these businesses are always conducting research and development to provide more effective medications for treating opioid addiction, such as long-acting buprenorphine.
Indivior PLC, for example, offers many buprenorphine pharmaceutical solutions in its portfolio, including SUBLOCADE and SUBOXONE. Orexo AB and Alkermes, both of which have substantial product lines, are also important participants in this business. Various methods, such as cooperation and new product releases, are expected to contribute to these firms' attempts to increase their revenue market share throughout the projection period.
KEY COMAPNIES:
-
Indivior PLC (U.S.)
-
Alkermes (Ireland)
-
Orexo AB (Sweden)
-
Titan Pharmaceuticals, Inc. (U.S.)
-
Mallinckrodt Pharmaceuticals (U.K.)
-
BioDelivery Sciences International Inc. (U.S.)
-
Viatris Inc. (Mylan N.V.) (U.S.)
-
Hikma Pharmaceuticals PLC (U.K.)
-
Camurus (Sweden)
KEY DEVELOPMENTS:
-
February 2023?– Orexo AB announced its collaboration with ApexB.io and Magellan Rx Management to further research the use of Modia. This product is a?digital therapeutic?designed for patients with Opioid Use Disorder.
-
March 2022:??Collegium Pharmaceutical, Inc. announced that it had completed the acquisition of BioDelivery Sciences International Inc.
What is Opioid Use Disorder Market Report about
This report discusses the commercial and clinical activity, providing insights on the total size of the potential opportunity, key segments driving growth, key challenges faced, and a thorough analysis of market competition by product, geography, indication, and forecasts through 2030. Detailed coverage of the approved therapies, including regulatory approvals, pricing, reimbursement, and market penetration.
So, a new investor can potentially gain information about competitors, their key products, their core strategy, key trends in the market, and more.
This report is essential for all stakeholders including research companies, manufacturing companies, distribution companies, government agencies, and others to:
-
Capitalize on rapidly emerging trends.
-
Optimize decision-making.
-
Reduce company risk.
-
Approach partners/investors for collaboration or funding.
-
Implement an informed and advantageous business strategy in 2023.
-
Detailed coverage of the approved products, including regulatory approvals, pricing, reimbursement, and market penetration.
-
Profiles of leading & upcoming competitors composing the global marketplace.